Baylor College of Medicine

S1801: Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery (H-44987)

Description

Content

S1801: A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma

This phase II trial studies how pembrolizumab works before and after surgery in treating patients with stage III-IV high-risk melanoma. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab before and after surgery may work better in treating melanoma.

See more information.

Contact

Dr. Daniel Wang

Phone 1: 713–798–1354

IRB: H-44987

Status:

Active

Created:

Back to topback-to-top